

0147108

EUROPEAN SEARCH REPORT

Application number

EP 84 30 9881



Europäisches Patentamt
European Patent Office
Office européen des brevets



DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Classification of document with indication where appropriate, of relevant passages	Relevant to claim	Classification of the application (in C14)
A	CURRENT GENETICS, vol. 2, no. 19, 7th November 1983, page 164, abstract no. 153176f, Columbus, Ohio, US; E. A. CANTWELL et al.: "Molecular cloning and expression of a <i>Bacillus subtilis</i> beta-glucanase gene in <i>Escherichia coli</i> ", & GENE 1983 23 (2), 211-19		
P	CHEMICAL ABSTRACTS, vol. 101, no. 23, December 1984, page 153, abstract no. 205283v, Columbus, Ohio, US; E. HINCHLIFFE et al.: "Expression of the cloned endo-1,3-1,4-beta-glucanase gene of <i>Bacillus subtilis</i> in <i>Saccharomyces cerevisiae</i> ", & CUKK. GENET. 1984, 8 (6), 471-5		
	CHEMICAL ABSTRACTS, vol. 101, no. 23, December 1984, page 153, abstract no. 205283v, Columbus, Ohio, US; E. HINCHLIFFE et al.: "Expression of the cloned endo-1,3-1,4-beta-glucanase gene of <i>Bacillus subtilis</i> in <i>Saccharomyces cerevisiae</i> ", & CUKK. GENET. 1984, 8 (6), 471-5		
	ABSTRACTS OF THE ANNUAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY (USA), vol. 81, 1981, page 116, ref. H19; S. K. FRICHTAGGIO et al.: "The cloning of trichoderma reesei genomic DNA in <i>Escherichia coli</i> HB101"		

The present search report has been drawn up for all claims

Patent search
THE Hague

Date of completion of the search
11-07-1986

Examiner
DESCAMPS J. A.

1 : theory or principle underlying the invention
2 : earlier patent document, but published on or
earlier than the filing date
3 : document cited in the application
4 : member of the same patent family, corresponding
document cited for other reasons

5 : document cited in the application
6 : document cited for other reasons

7 : theory or principle underlying the invention
8 : earlier patent document, but published on or
earlier than the filing date
9 : document cited in the application
10 : member of the same patent family, corresponding
document cited for other reasons

11 : theory or principle underlying the invention
12 : earlier patent document, but published on or
earlier than the filing date
13 : document cited in the application
14 : member of the same patent family, corresponding
document cited for other reasons

15 : theory or principle underlying the invention
16 : earlier patent document, but published on or
earlier than the filing date
17 : document cited in the application
18 : member of the same patent family, corresponding
document cited for other reasons

19 : theory or principle underlying the invention
20 : earlier patent document, but published on or
earlier than the filing date
21 : document cited in the application
22 : member of the same patent family, corresponding
document cited for other reasons

23 : theory or principle underlying the invention
24 : earlier patent document, but published on or
earlier than the filing date
25 : document cited in the application
26 : member of the same patent family, corresponding
document cited for other reasons

27 : theory or principle underlying the invention
28 : earlier patent document, but published on or
earlier than the filing date
29 : document cited in the application
30 : member of the same patent family, corresponding
document cited for other reasons

31 : theory or principle underlying the invention
32 : earlier patent document, but published on or
earlier than the filing date
33 : document cited in the application
34 : member of the same patent family, corresponding
document cited for other reasons

35 : theory or principle underlying the invention
36 : earlier patent document, but published on or
earlier than the filing date
37 : document cited in the application
38 : member of the same patent family, corresponding
document cited for other reasons

154

0 147 198
A3

(i) Publication number:

A3

(ii) Publication number:

A3

European Patent Office
Office européen des brevets



(i) Application number:

A3

(ii) Date of filing:

20.12.84

(iii) Date of publication of application:

03.07.85

(iv) Date of deferred publication of search report:

08.10.86

(v) Designated Contracting States:

AT BE CH DE FR GB IT LU NL SE

(vi) Representative:

Collier, Jeremy Austin Grey et al.

(vii) J.A. Kemp & Co. M. South Square Grey's Inn

(viii) London WC1R 8UJ (GB)

(ix) Fermmentation processes and their products.

(x) The invention provides a process for the production of ethanol and a protein or peptide which is heterologous to yeast which comprises fermenting an aqueous sugar-containing medium with an industrial yeast strain which has been genetically modified to be capable of expressing a heterologous protein or peptide, recovering the ethanol so formed, and obtaining the said heterologous protein or peptide from the fermentation products. The process may be applied to the industrial production of alcoholic beverages such as beer or distilled alcohol. The yeast inevitably obtains as a by-product in the process heat improved value because of the heterologous protein or peptide which it contains and provides a source of the latter. Heterologous protein and lipoproteins which may be produced by the new products include enzymes such as halo-lipase, beta-glucanase and sulphatases and proteins of therapeutic value such as human serum albumen.

(xi) EP 0 147 198 A3

(xii) European Patent Office

(xiii) Office européen des brevets

(xiv) Office of the European Patent Office

(xv) Office européen des brevets

(xvi) Office of the European Patent Office

(xvii) Office européen des brevets

(xviii) Office of the European Patent Office

(xix) Office européen des brevets

(xx) Office of the European Patent Office

(xxi) Office européen des brevets

(xxii) Office of the European Patent Office

(xxiii) Office européen des brevets

(xxiv) Office of the European Patent Office

(xxv) Office européen des brevets

(xxvi) Office of the European Patent Office

(xxvii) Office européen des brevets

(xxviii) Office of the European Patent Office

(xxix) Office européen des brevets

(xxx) Office of the European Patent Office

(xxxi) Office européen des brevets

(xxxii) Office of the European Patent Office

(xxxiii) Office européen des brevets

(xxxiv) Office of the European Patent Office

(xxxv) Office européen des brevets

(xxxvi) Office of the European Patent Office

(xxxvii) Office européen des brevets

(xxxviii) Office of the European Patent Office

(xxxix) Office européen des brevets

(xxi) Office of the European Patent Office

(xxii) Office européen des brevets

(xxiii) Office of the European Patent Office

(xxiv) Office européen des brevets

(xxv) Office of the European Patent Office

(xxvi) Office européen des brevets

(xxvii) Office of the European Patent Office

(xxviii) Office européen des brevets

(xxix) Office of the European Patent Office

(xxx) Office européen des brevets

(xxxi) Office of the European Patent Office

(xxxii) Office européen des brevets

(xxxiii) Office of the European Patent Office

(xxxiv) Office européen des brevets

(xxxv) Office of the European Patent Office

(xxxvi) Office européen des brevets

(xxxvii) Office of the European Patent Office

(xxxviii) Office européen des brevets

(xxxix) Office of the European Patent Office

(xxi) Office européen des brevets

(xxii) Office of the European Patent Office

(xxiii) Office européen des brevets

(xxiv) Office of the European Patent Office

(xxv) Office européen des brevets

(xxvi) Office of the European Patent Office

(xxvii) Office européen des brevets

(xxviii) Office of the European Patent Office

(xxix) Office européen des brevets

(xxxi) Office of the European Patent Office

(xxxii) Office européen des brevets

(xxxiii) Office of the European Patent Office

(xxxiv) Office européen des brevets

(xxxv) Office of the European Patent Office

(xxxvi) Office européen des brevets

(xxxvii) Office of the European Patent Office

(xxxviii) Office européen des brevets

(xxxix) Office of the European Patent Office

(xxi) Office européen des brevets

(xxii) Office of the European Patent Office

(xxiii) Office européen des brevets

(xxiv) Office of the European Patent Office

(xxv) Office européen des brevets

(xxvi) Office of the European Patent Office

(xxvii) Office européen des brevets

(xxviii) Office of the European Patent Office

(xxix) Office européen des brevets

(xxxi) Office of the European Patent Office

(xxxii) Office européen des brevets

(xxxiii) Office of the European Patent Office

(xxxiv) Office européen des brevets

(xxxv) Office of the European Patent Office

(xxxvi) Office européen des brevets

(xxxvii) Office of the European Patent Office

(xxxviii) Office européen des brevets

(xxxix) Office of the European Patent Office

(xxi) Office européen des brevets

(xxii) Office of the European Patent Office

(xxiii) Office européen des brevets

(xxiv) Office of the European Patent Office

(xxv) Office européen des brevets

(xxvi) Office of the European Patent Office

(xxvii) Office européen des brevets

(xxviii) Office of the European Patent Office

(xxix) Office européen des brevets

(xxxi) Office of the European Patent Office

(xxxii) Office européen des brevets

(xxxiii) Office of the European Patent Office

(xxxiv) Office européen des brevets

(xxxv) Office of the European Patent Office

(xxxvi) Office européen des brevets

(xxxvii) Office of the European Patent Office

(xxxviii) Office européen des brevets

(xxxix) Office of the European Patent Office

(xxi) Office européen des brevets

(xxii) Office of the European Patent Office

(xxiii) Office européen des brevets

(xxiv) Office of the European Patent Office

(xxv) Office européen des brevets

(xxvi) Office of the European Patent Office

(xxvii) Office européen des brevets

(xxviii) Office of the European Patent Office

(xxix) Office européen des brevets

(xxxi) Office of the European Patent Office

(xxxii) Office européen des brevets

(xxxiii) Office of the European Patent Office

(xxxiv) Office européen des brevets

(xxxv) Office of the European Patent Office

(xxxvi) Office européen des brevets

(xxxvii) Office of the European Patent Office

(xxxviii) Office européen des brevets

(xxxix) Office of the European Patent Office

(xxi) Office européen des brevets

(xxii) Office of the European Patent Office

(xxiii) Office européen des brevets

(xxiv) Office of the European Patent Office

(xxv) Office européen des brevets

(xxvi) Office of the European Patent Office

(xxvii) Office européen des brevets

(xxviii) Office of the European Patent Office

(xxix) Office européen des brevets

(xxxi) Office of the European Patent Office

(xxxii) Office européen des brevets

(xxxiii) Office of the European Patent Office

(xxxiv) Office européen des brevets

(xxxv) Office of the European Patent Office

(xxxvi) Office européen des brevets

(xxxvii) Office of the European Patent Office

(xxxviii) Office européen des brevets

(xxxix) Office of the European Patent Office

(xxi) Office européen des brevets

(xxii) Office of the European Patent Office

(xxiii) Office européen des brevets

(xxiv) Office of the European Patent Office

(xxv) Office européen des brevets

(xxvi) Office of the European Patent Office

(xxvii) Office européen des brevets

(xxviii) Office of the European Patent Office

(xxix) Office européen des brevets

(xxxi) Office of the European Patent Office

(xxxii) Office européen des brevets

(xxxiii) Office of the European Patent Office

(xxxiv) Office européen des brevets

(xxxv) Office of the European Patent Office

(xxxvi) Office européen des brevets

(xxxvii) Office of the European Patent Office

(xxxviii) Office européen des brevets

(xxxix) Office of the European Patent Office

(xxi) Office européen des brevets

(xxii) Office of the European Patent Office

(xxiii) Office européen des brevets

(xxiv) Office of the European Patent Office

(xxv) Office européen des brevets

(xxvi) Office of the European Patent Office

(xxvii) Office européen des brevets

(xxviii) Office of the European Patent Office

(xxix) Office européen des brevets

(xxxi) Office of the European Patent Office

(xxxii) Office européen des brevets

(xxxiii) Office of the European Patent Office

(xxxiv) Office européen des brevets

(xxxv) Office of the European Patent Office

(xxxvi) Office européen des brevets

(xxxvii) Office of the European Patent Office

(xxxviii) Office européen des brevets

(xxxix) Office of the European Patent Office

(xxi) Office européen des brevets

(xxii) Office of the European Patent Office

(xxiii) Office européen des brevets

(xxiv) Office of the European Patent Office

(xxv) Office européen des brevets

(xxvi) Office of the European Patent Office

(xxvii) Office européen des brevets

(xxviii) Office of the European Patent Office

(xxix) Office européen des brevets

(xxxi) Office of the European Patent Office

(xxxii) Office européen des brevets

(xxxiii) Office of the European Patent Office

(xxxiv) Office européen des brevets

(xxxv) Office of the European Patent Office

(xxxvi) Office européen des brevets

(xxxvii) Office of the European Patent Office

(xxxviii) Office européen des brevets

(xxxix) Office of the European Patent Office

(xxi) Office européen des brevets

(xxii) Office of the European Patent Office

(xxiii) Office européen des brevets

(xxiv) Office of the European Patent Office

(xxv) Office européen des brevets

(xxvi) Office of the European Patent Office

(xxvii) Office européen des brevets

(xxviii) Office of the European Patent Office

(xxix) Office européen des brevets

(xxxi) Office of the European Patent Office

(xxxii) Office européen des brevets

(xxxiii) Office of the European Patent Office

DOCUMENTS CONSIDERED TO BE RELEVANT		Report in him of several passages	Classification of the application, in C.I.
Category	Citation of document with indication where it is appropriate.		
F, X	REFWERKS' GUARDIAN, September 1981, pages 34-37; R.S. TUBB: "Genetic development of yeast strains" * Page 35, column 1, lines 47-49; page 37, column 1; figure 4 *	1	C 12 N 15, C 12 C 11, C 12 P 7, C 12 P 21, C 12 N 9, C 12 N 10
A	CE-A-2 094 341 (MITSUBISHI CHEMICAL INDUSTRIES LTD.) * Page 3, lines 31-37; claims 1,19 *	1	
A	CHEMICAL ABSTRACTS, vol. 98, no. 7, February 1983, page 179, abstract no. 47922r, Columbus, Ohio, US; R.A. IRVING et al.; "Development of an amylolytic Saccharomyces cerevisiae by genetic engineering" & PROC.-EJOENERGY R & D SEMIN 1982, 4 th, 541-5	---	
A	EF-A-O 096 491 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)	---	
A	AGRICULTURAL AND BIOLOGICAL CHEMISTRY, vol. 47 no. 11, November 1983, Pages 2689-2692; I. YAMASHITA et al.; "Molecular cloning of a glucoamylase-producing gene in the yeast Saccharomyces"	---	
The present search report has been drawn up for all claims		-/-	
Place of search	Date of completion of the search	Examiner	
THE HAGUE	11-07-1986	DESCAMPS J.A.	

<input checked="" type="checkbox"/> X	Particularly relevant if taken alone	I	Theory or principle underlying the invention
<input checked="" type="checkbox"/> X	Particularly relevant if combined with another document of the same category	E	Earlier patent document, but published on or before the filing date
<input checked="" type="checkbox"/> X	Document cited in the application for other reasons	D	Document cited in the application for other reasons
<input checked="" type="checkbox"/> X	Technological background	L	Member of the same patent family, corresponding document
<input checked="" type="checkbox"/> X	Non-written disclosure	O	
<input checked="" type="checkbox"/> X	Intermediate document	P	

- 1 -

FERMENTATION PROCESSES AND THEIR PRODUCTS

This invention relates to fermentation processes and their products, and more particularly to the production of alcohol, i.e. ethanol, by fermentation of sugars with yeast.

5 In the manufacture of alcohol by fermentation, sugars in aqueous solution are converted into ethanol by fermentation with yeast. The yeast grows during the fermentation and although a small proportion of the yeast may be used in a subsequent fermentation 10 process, the remainder of the yeast constitutes an excess that must be disposed of. While this excess yeast has some uses e.g. in animal feedstuffs and the manufacture of yeast extracts, the quantity of excess yeast produced is large and its market value is 15 relatively low.

Large scale fermentations of this kind fall into three broad categories:

- (1) Fermentations in which the fermented aqueous medium obtained is the desired end product.
- 20 Into this category fall ordinary brewing processes for the production of beer (a term which, as used herein, includes ales, stouts, lagers and other fermented drinks based on malt), cider and other fermented drinks.
- 25 (2) Fermentations in which the desired end product is a distilled drinkable alcoholic concentrate. Into this category fall fermentations for production of whiskies, brandies and other spirits, and alcohol for use in fortifying other drinks.
- 30 (3) Fermentations for the production of alcohol for industrial use. Into this category falls fermentations carried out in some countries on a large scale for the production of fuel alcohol.
- 35 The production of excess yeast is a characteristic of all these industrial processes.

- 2 -

Considerable interest has been shown in recent years in the genetic modification of microorganisms so that they become able to produce heterologous proteins and peptides, that is to say proteins and peptides which are not produced by their natural genetic constituents. A variety of microorganisms have been used for such genetic manipulation, and, amongst these, yeasts have attracted a certain amount of interest. However, yeasts used in laboratory experiments are not normally the same as the yeasts used in large scale industrial fermentations involving the production of alcohol, and the conditions of growth of yeast in the laboratory are very different from those encountered by yeasts in an industrial alcoholic fermentation.

The present invention is based on the discovery that it is possible to use, in an industrial fermentation involving the production of alcohol, genetically modified yeast capable of expressing a heterologous protein or peptide. Surprisingly, it has been found that the use of such yeast is compatible with industrial fermentation conditions. This means that the excess yeast obtained in the fermentation provides a source of the heterologous protein or peptide and thus has much enhanced industrial value. Further, since the alcohol product remains the principle objective of the fermentation, and the conventional equipment can largely be used with little alteration, the additional cost of producing the higher value yeast product is small, so that the new process may provide an economically viable route to heterologous proteins or peptides which, although valuable, do not command a premium price.

- 3 -

The present invention accordingly provides a process for the production of ethanol and a protein or peptide which is heterologous to yeast which comprises fermenting an aqueous sugar-containing medium with a yeast strain which has been genetically modified to be capable of expressing a heterologous protein or peptide, recovering the ethanol so formed, and obtaining the said heterologous protein or peptide from the fermentation products.

The yeasts are a group of lower eukaryotic micro-organisms showing biological and biochemical diversity. In common usage the term "yeast" is used to describe strains of Saccharomyces cerevisiae that have commercial value in baking, brewing and distilling. Related yeasts are used in wine making and sake brewing, as well as in the production of fuel alcohol from sucrose or hydrolysed starch.

All the yeasts used for brewing, baking and distilling may be taxonomically classified as Saccharomyces cerevisiae. Included within this classification are the top fermenting ale yeasts (S. cerevisiae) and the bottom-fermenting lager yeasts (S. uvarum or S. carlsbergensis).

In a strict sense brewers yeast is differentiated from all other yeasts in that it is a yeast strain which is used to make beer, i.e. a strain of yeast used currently in a beer manufacturing process. Such yeasts must be able to produce a palatable acceptable beer by their fermentative action upon hopped malt extract (brewers wort). The primary products of this fermentation are ethanol and carbon dioxide, which are essential constituents of beer. However, not all yeasts belonging to the species S. cerevisiae are capable of

fulfilling these requirements. Indeed, the critical factor in this respect is believed to be the ability of the yeast strain to form in subtly balanced proportions, quantitatively minor metabolic products such as esters, acids, higher alcohols and ketones. A yeast may be unsuitable for brewing because one or more of these minor metabolic products is produced in excessive amounts, either in absolute terms or relative to one another. (Rainbow, C.A., 1970, in "The Yeasts", eds, Rose, A.H. & Harrison J.S. Vol. 3, p. 147).

In a general sense brewers yeast is differentiated from other yeasts by the properties which it possesses. Most strains of industrial yeast, unlike laboratory yeast, are incapable of undergoing mating; they are said to be homothallic. Industrial yeasts are usually aneuploid or polyploid, and there is therefore a reduced incidence at which gene mutations are phenotypically detected. Most polyploid strains do not sporulate or they produce spores of very low viability, thus frustrating any meaningful genetic analysis. These factors together tend to confer a measure of phenotypic stability on industrial yeasts which may contribute to their selection for industrial application. Similarly gene dosage which is associated with high ploidy may contribute to the general fitness of such strains for fermentation as compared to haploids and diploids, which generally ferment poorly.

In addition, brewers yeasts have certain technological behaviour which equips them well for interacting with their normal environment, brewers' hopped wort.

The manner in which the new process is operated depends on the type of industrial fermentation. Where the fermentation is designed to produce an

aqueous potable liquid such as beer, at the end of the fermentation, the fermented liquid is separated from the yeast (and normally any other solid material present in the fermented medium). In these circumstances, it is clearly desirable, and indeed normally essential, that the heterologous protein or peptide shall not become dissolved in the fermented liquid, since it is normally unacceptable for the heterologous protein or peptide to be present in a liquid which is to be drunk. In such circumstances, the heterologous protein or peptide may be obtained from the yeast cells. Where, however, the alcohol is recovered by distillation, as is the case in the second and third types of industrial fermentation

15 mentioned above, it may be acceptable, and even desirable, for the protein or peptide to be present in the fermented liquid in dissolved form.

The yeast strain used in the new process must, of course, be suitable for the type of industrial fermentation contemplated. This objective may be secured by carrying out the genetic modification on a yeast strain which is known to have the desired characteristics, since it has been found that the desirable characteristics which make a yeast strain

25 suitable for a particular type of industrial fermentation are not normally lost during the genetic modification. For example, where the fermentation is one for producing beer, the yeast strain chosen for genetic modification is preferably a known strain of brewers' yeast currently used in such fermentations. As already noted, such industrial strains of brewers' yeast have characteristics different from those of "laboratory yeast", including in particular the ability to ferment hopped brewers' wort.

- 6 -

Brewers wort is essentially a hot water extract of malted barley or other grains prepared by steeping and germination and flavoured with hops. The most important parameters with respect to yeast growth and metabolism are carbohydrate and nitrogen (and amino acid) composition. These vary from country to country and brewery to brewery, see, e.g., "Malting and Brewing Science", Vol. 2, Hopped Wort and Beer, by Hough, J.S., Briggs, D.E., Steven R. and Young, T.W., 1982, Chapman and Hall, London and New York, p.456-498. In general it may be said that brewers wort contains 5 to 10 g of total fermentable sugars per 100 ml of wort, at least half of which is maltose. Additional factors which influence yeast growth and performance are:

- (1) Growth factors. These include substances like biotin, thiamine, riboflavin, pyridoxine, pantothenic acid and nicotinic acid. In general brewers wort is a rich source of these factors, which are depleted during yeast growth.
- (2) Minerals. The mineral requirements of brewers yeast resemble those of most living organisms. Brewers wort meets these requirements, such trace amounts of metal ions such as iron, potassium, magnesium, zinc, manganese and copper, which are essential for vital metabolic enzymes.

The most significant difference between a laboratory culture medium and a brewers wort is the sugar composition of the medium. Most laboratory media utilise glucose as the chief source of carbohydrate, whereas maltose is the chief fermentable constituent of wort.

Brewery fermentations normally take the form of anaerobic (oxygen free) fermentations. However, oxygen is a prime requirement for yeast growth in the initial stages of fermentation. Most laboratory fermentations are designed to maximise the yeast

- 7 -

biomass yield, whereas beer fermentations concentrate upon ethanol yield and product flavour. Thus the inoculation rate ("pitching rate") of a beer fermentation is higher than would normally be used in the laboratory. Consequently, the number of cell doublings (cell generations) is reduced to between 2 and 4 per fermentation.

The fermentation of beer wort is normally carried out at a temperature within the range of 8 to 25°C, a temperature at the upper end of this range, e.g. 15 to 25°C being used when the product is ale, and a temperature of e.g. 8 to 15°C being used where the product is lager. Under laboratory conditions, yeasts are cultivated at significantly higher temperature, e.g. 25 to 35°C.

Similarly, where the industrial fermentation is one for the production of alcohol which is separated by distillation, it is necessary to use genetically modified yeast obtained from a strain suitable for such fermentation. In such fermentations, the source of sugars may be, for example, grain, potatoes, sugar cane, or sugar beet and may optionally have been pre-treated, e.g. by chemical or enzymic hydrolysis, to convert cellulose and/or starch therein into fermentable sugars.

The genetic modification of yeast may be effected in a known manner. Suitable methods are described in the literature, and particular methods are given in the Examples below.

A wide range of heterologous proteins or peptides may be chosen for expression in the yeast. By way of example mention may be made of enzymes such as beta-lactamase, beta-glucanase, and beta-galactosidase. Other useful heterologous

- 8 -

proteins and peptides include materials of human origin and/or useful in therapy, such as human serum albumin and immunoglobulins. Methods are described in the literature for the genetic modification of microorganisms to enable them to express such proteins and peptides.

The heterologous protein or peptide made available by the genetically modified yeast may be used in several different ways. In the simplest case, the protein or peptide is retained by the yeast in the yeast cells and the latter are used as such. Normally, however, it is preferred to isolate the heterologous protein or peptide. Where the latter is excreted by the yeast into the surrounding medium, the fermented medium is worked up for isolation of protein or peptide. As already noted, this method is normally unsuitable where the fermented medium is to be consumed, e.g. as a beverage. In such a case, the desired protein or peptide is obtained from the yeast produced during the fermentation. For example, the yeast cells may be ruptured to release their contents, and the protein or peptide then isolated from the latter.

The following examples illustrate the invention in more detail. The accompanying drawing shows gene maps illustrating the formation of a plasmid used in one example. These examples describe the modification of brewers yeast so that it produces the heterologous proteins beta-lactamase and/or beta-glucanase and the use of the modified yeast in a brewing process.

β -lactamase is the name given to a group of proteins that constitute enzymes operative to catalyse the hydrolysis of the amide bond in the β -lactam ring of 6-amino-penicillanic acid or 7-amino-cephalosporanic acid and of their N-acyl derivatives. Such derivatives are 5 penicillins and cephalosporins, generally known as β -lactam antibiotics (Citri, N., 1971, "The Enzymes", 3rd edition, ed. Boyer, P.A., IV, p 23).

β -lactamase is widespread amongst the various bacterial species, being found in both Gram-negative and Gram-positive bacteria. The gene specifying the production of β -lactamase has been variously assigned to both chromosomal and extrachromosomal elements. In 15 enteric bacteria a β -lactamase gene can frequently be acquired by infection with an extrachromosomal particle in the form of a plasmid and constituting a resistance factor (or R-factor). One such R-factor carrying a β -lactamase gene, and thus conferring resistance upon its 20 host bacterium to β -lactam antibiotics, is R1 (Meynell, E. & Datta, N., 1966, Genetical Research, 7, p 134). This plasmid was identified in a clinical isolate of Salmonella paratyphi B (Meynell, E. & Datta, N., 1966, Genetical Research, 7, p 134). The species specificity 25 of β -lactamase has been brought into question since R-factors are capable of mediating their own transfer, and thus the transfer of the β -lactamase gene among the Enterobacteriaceae (enteric bacteria) (Datta, N. & Richmond, M.H., 1966, Biochemical Journal, 98, p 204).

With the advent of genetic engineering (recombinant DNA technology) there has developed a requirement for easily manipulated plasmid vectors for use in DNA

- 10 -

cloning. The β -lactamase gene present on plasmid R1 has been introduced into new plasmids in the construction of novel cloning vectors. One such vector is RSF 2124 (So, M. et al., 1975, Molecular and General Genetics, 142, p 239) constructed from the plasmid Col E1 and a derivative of R1, R1 drd19 (Meyneil, E. & Datta, N., 1967, Nature, 214, p 885).

RSF 2124 has been manipulated subsequently to produce the plasmid vector PBR322 (Bolivar, F. et al., 1977, Gene, 2, p 95), which has been further manipulated to form PAT153 (Twigg, A.A. & Sherratt, D., 1980, Nature, 283, p 216). All these plasmid vectors retain the β -lactamase gene of R1 and are capable of specifying the production of β -lactamase enzyme in Escherichia coli.

Additional manipulation of plasmid cloning vectors derived from PBR322, and therefore possessing the β -lactamase gene of R1, has been necessary to construct plasmids capable of transforming yeast (i.e. of being introduced into yeast). Thus, for example, the plasmid PAT153 (Twigg, A.J. & Sherratt, D., 1980, Nature, 283, p 216) has been attached to segments of yeast chromosomal DNA (LEU-2 gene of Saccharomyces cerevisiae specifying the production of β -isopropyl-malate-dehydrogenase, an enzyme involved in the biosynthesis of leucine) and 2 μ m plasmid DNA (2 μ m is an endogenous plasmid of yeast) to form plasmid PJDB207 (Beggs, J.D., 1981, "Molecular Genetics in Yeast", eds. von Wettstein, D., Stenderup, A., Kielland-Brandt, M. & Friis, J., Alfred Benzon Symposium No. 16, Munksgaard, Copenhagen, p 383).

- 11 -

β -lactamase was the first heterologous protein to be expressed in S. cerevisiae (Hollenberg, C.P., 1979, ICN-UCLA Symposium Molecular and Cellular Biology, 15, p 325; Hollenberg, C.P., 1979, "Plasmids of Medical, Environmental and Commercial Importance", eds. Timmis, K.N. & Puhler, A., Elsevier, p 481). The bacterial ampicillin-resistance gene specifying the production of β -lactamase enzyme originated from Plasmid PBR325, a derivative of PBR322, and therefore ultimately from Salmonella paratyphi B (see earlier references). The β -lactamase protein synthesised in S. cerevisiae has been purified 100-fold over crude extracts, and its enzymic activity, molecular weight and binding to specific antibodies have been shown to be indistinguishable from the purified protein from E. coli (Rogggenkamp, R. et al., 1981, PNAS USA, 78, p 4466). The level of β -lactamase expression in yeast is low due to the weak function of the bacterial gene promoter (control region of the gene); however, gene expression can be greatly enhanced by the use of the ADH1 promoter (alcohol dehydrogenase) of yeast (Hollenberg, C.P. et al., 1983, "Gene Expression in Yeast", eds. Korhola, M. & Vaisanen, E., Proceedings of the Alko Yeast Symposium, Helsinki, p 73).

- 12 -

Yeast transformation (that is the introduction of DNA into yeast) can be a relatively inefficient process, with success depending upon a suitable selection system. Most plasmids currently in use for yeast transformation are selectable, because they carry a wild-type gene which complements an auxotrophic mutation in the chosen recipient strain which has been a laboratory haploid strain of *S. cerevisiae*. However, brewers' yeasts are prototrophic and have no auxotrophic requirements. To select transformants in brewers' yeast it is necessary to have a dominant gene conferring the ability to grow in otherwise adverse conditions. CUP-1 is a dominant yeast gene, specifying the production of a protein capable of chelating copper ions. This gene has been cloned on the yeast/*E. coli* shuttle vector PJDB207, by insertion of restriction-endonuclease-Sau3A-generated DNA fragments from strain X2180-1A to form plasmid PET13:1 (Henderson, R.C.A., 1983, "The Genetics and Applications of Copper Resistance in Yeast", Ph.D. thesis, University of Oxford). A genetic map of pET13:1 is included in the accompanying drawing.

Plasmid PET13:1 carries the LEU-2 and CUP-1 chromosomal genes of yeast and the 2^μm yeast plasmid origin of DNA replication as well as DNA derived from plasmid PAT153; consequently PET13:1 harbours the bacterial β -lactamase gene which is known to express β -lactamase in yeast.

Henderson (1983) describes in some detail methods for transforming brewers' yeast (ale yeast and lager yeast) with plasmid pET13:1. He also described the screening of brewers' yeast transformants for β -lactamase activity using a starch iodide plate assay described below. Clearly the bacterial β -lactamase protein is produced in brewers' yeast transformed with pET13:1 and can be detected when transformants are grown upon the appropriate indicator medium.

- 13 -

The genetic modification of a particular strain of brewers' yeast, by the introduction into it of the plasmid PET13:1, will now be described. The yeast used was NCYC 240, which is an ale yeast which is available to the public from the National Collection of Yeast Cultures (Agricultural Research Council, Food Research Institute, Colney Lane, Norwich, England).

Before strain NCYC 240 could be transformed with plasmid PET13:1 (CUP-1/ β -lactamase) its sensitivity to copper was assessed. To this end, samples of NCYC 240 were patched on YED glucose or YED glucose agar (1% w/v yeast extract, 2% w/v peptone, 2% w/v glucose, solidified with 2% w/v agar) and grown for 2 days at 28°C. They were then replica plated to NEP agar medium (MgSO₄·7H₂O 10 g/l, (NH₄)₂SO₄ 2g/l, KH₂PO₄ 3g/l, CaCl₂·2H₂O 0.25g/l, yeast extract 2g/l, peptone 3g/l, glucose 40g/l solidified with 2% agar. Naiki, N. & Yamagata, S., 1976, Plant and Cell Physiology, 17, p 1281) containing increasing concentrations of copper sulphate (CuSO₄).

The strain tested did not grow on NEP containing 0.1mM CuSO₄. It was therefore concluded that in excess of 0.1mM CuSO₄ in NEP would be sufficient to select for copper resistant transformants of brewers' yeast.

Plasmid DNA of PET13:1 was isolated from the bacterium *Escherichia coli* K-12 strain JA221 (recA1, leuB6, trp E5, hsdM+, lacy. Beggs, J.D., 1978, Nature, 275, p 104) by caesium chloride/ethidium bromide equilibrium gradient centrifugation of cleared cell lysates using the method of Clevell, D.B. & Helsingki, D.R. (1967, Proceedings of the National Academy of Science, USA, 62, p 1159) with the modifications of Zahn, G. et al. (1977, Molecular and General Genetics, 151, p 45).

14

Samples of NCYC 240 were prepared for transformation with PET13:1 by each of two methods: (A) the method of Beggs, J.D. (1978, Nature, 275, p 104), and (B) the method described by Henderson R.C.A. (1983, "The Genetics and Applications of Copper Resistance in Yeast", Ph.D. thesis, University of Oxford) with the exception that the protoplasting enzyme used was Zymolyase (40ug/ml) (Kirin Brewery Co. Ltd.). 100µl of yeast spheroplasts produced by methods A and B were mixed with 15µl of pET13:1 DNA (approximately 250µg DNA/ml) and treated with polyethylene glycol (1ml 40% PEG 4000 in 10mM CaCl₂, 10mM Tris/HCl pH 7-6). After the treatment with polyethylene glycol, cells were spun down and gently resuspended in 500µl NEP glucose medium containing 1.2M sorbitol. Following incubation for one hour at 28°C, cells were added to 10ml of molten NEP glucose 3% agar containing 0.3mM CuSO₄ and 1.2M sorbitol. This was then poured onto NEP glucose 2% agar medium containing 1.2M sorbitol and 0.3mM CuSO₄. Transformation plates were incubated for four to five days at 28°C after which time yeast colonies arising on the selective copper medium were picked off and patched upon NEP glucose agar containing 0.3mM CuSO₄. These patched colonies were designated putative pET13:1 transformants, and were checked as described below to confirm that they were genuine brewers' yeast transformants. The frequencies of transformation for each of the two methods A and B for NCYC 240 were <4 transformants/µg DNA and 20 transformants/µg DNA.

It is usual when attempting to confirm that a strain of yeast or bacteria is a genuine transformant to check for the presence of one or more genetic characters specified by the incoming plasmid DNA. The putative transformants described above were therefore assessed for high-level copper resistance and β -lactamase activity.

1000

since each phenotype (copper resistance activity) is specified by genes carried on the plasmid pET13:1. The following methods were employed:

method described by Henderson R.C.A. (1983, "The Genetics and Applications of Copper Resistance in Yeast", Ph.D. thesis, University of Oxford) with the exception that the protoplasting enzyme used was zymolyase (40 μ g/ml) (Kirin Brewery Co. Ltd.). 100 μ l of yeast spheroplasts produced by methods A and B were mixed with 15 μ l of pET13:1 DNA (approximately 250 μ g DNA/ml) and treated with 10 polyethylene glycol (1ml 40% PEG 4000 in 10mM CaCl₂, 10mM Tris/HCl pH 7.6). After the treatment with polyethylene glycol, cells were spun down and gently resuspended in 15 500 μ l NEP glucose medium containing 1.2M sorbitol. Following incubation for one hour at 28°C, cells were added to 10ml of molten NEP glucose 3% agar containing 0.3mM CuSO₄ and 1.2M sorbitol. This was then poured onto 20 NEP glucose 2% agar medium containing 1.2M sorbitol and 0.3mM CuSO₄. Transformation plates were incubated for four to five days at 28°C after which time yeast colonies arising on the selective copper medium were picked off and patched upon NEP glucose agar containing 0.3mM CuSO₄. These patched colonies were designated putative pET13:1 transformants, and were checked as described below to 25 confirm that they were genuine brewers' yeast transformants. The frequencies of transformation for each of the two methods A and B for NCYC 240 were <4 transformants/ μ g DNA and 20 transformants/ μ g DNA.

It is usual when attempting to confirm that a strain of yeast or bacteria is a genuine transformant to check for the presence of one or more genetic characters specified by the incoming plasmid DNA. The putative transformants described above were therefore assessed for high-level copper resistance and β -lactamase activity.

since each phenotype (copper resistance activity) is specified by genes carried on the plasmid pET13:1. The following methods were employed:

(a) High-level copper resistance. Putative PE13.1. Transformants growing as patches on NEP glucose agar + 0.3mM CuSO₄ were sub-cultured by replica plating to the same medium and NEP glucose agar + 1mM CuSO₄. Those patched colonies which grew on the media containing both 0.3mM and 1mM CuSO₄ clearly possess high-level copper resistance. This character is presumed to be a feature of plasmid transformants carrying CUP-1, since copy number regulates copper resistance in yeast (Fogel, S. et al., 1983, Current Genetics, 2, p 347). It is not unreasonable to expect plasmid transformants to have a high-level of copper resistance due to the multiple copies of the plasmid genome. Those patched colonies which showed high-level copper resistance were then subjected to the β -lactamase test.

(b) The β -lactamase test for detecting β -lactamase produced by yeast strains carrying chimaeric yeast/E. coli plasmids is routinely applied to yeast transformants. (Chevallier, M.R. & Aigle, M., 1979, FEBS Letters, 108, p 179). The method described by Chevallier and Aigle (1979) is strictly adhered to and involves the following procedure:

The basis of the test is that penicillium giving a (β -lactamase) hydrolyses penicillin giving a reducing compound, penicilloic acid. The reducing action of penicilloic acid is rendered visible by the decoloration of a deep blue iodine-starch complex incorporated into a solid agar medium. Thus, if β -lactamase-producing strains are placed on

30

- 16 -

the test medium a white halo appears around the β -lactamase-producing strain.

Test medium: Yeast nitrogen base (Difco) 0.65% w/v, glucose 0.1% w/v, soluble starch 0.2% w/v, agar 2% w/v, buffered with 0.02M phosphate at pH 6-7.

Soft agar test medium: as above, but with 1% w/v agar.
Reagent: 3mg/ml I₂; 15mg/ml KI; 0.02M phosphate buffer pH 7; 3mg/ml ampicillin.

Plates containing the test medium are patched with an inoculum of putative brewers' yeast transformant. They are incubated at 30°C for 18 hours. A mixture of 4ml melted soft agar test medium plus 1.5ml reagent is prepared. The mixture is stirred and gently poured over the test medium. Plates, which are deep blue, are left for 1 hour at 30°C and thereafter placed at 4°C. After about 24 hours any strain producing β -lactamase shows a well defined white (colourless) halo, whereas control strains without plasmid show a very slight and limited decolouration. β -lactamase-producing transformants are therefore clearly distinguished from strains which do not possess the β -lactamase gene.

(c) Inheritable instability. A characteristic feature of yeast strains transformed with 2 μ m based plasmids such as pET13:1 and pJD8207 (pJD8207 being the parental plasmid of PET13:1), is that the plasmid is inheritably unstable. The consequence of this instability is that a small proportion of yeast cells within a population segregate plasmid-free daughter cells at cell division. In the case of

- 17 -

plasmid PET13:1, plasmid-free cells can be detected on the basis of their sensitivity to copper (NEP glucose agar + 0.3mM CuSO₄). Thus, copper-resistant transformants (see (a) above) are streaked on YED glucose medium and grown for 3-4 days at 27°C. Colonies arising on YED medium are then replica plated to the same medium and NEP glucose agar + 0.3mM CuSO₄. Colonies which have segregated the copper-resistant plasmid PET13:1 do not grow on the copper-supplemented medium. A variation of this method for evaluating the segregational phenotype of brewers' yeast transformants can be employed, in which putative transformants are first inoculated into NEP glucose medium (liquid medium without agar) and grown overnight at 27°C. The following day cells can be plated out on NEP glucose agar at a suitable dilution to obtain single colonies following incubation for three days at 27°C. Yeast colonies can then be replicated to NEP glucose agar and the same medium supplemented with 0.3mM CuSO₄. Those brewers' yeast transformants which possess plasmid PET13:1 can be distinguished from spontaneous copper-resistant derivatives on the basis of their ability to segregate copper resistance.

Methods (a), (b) and (c) are sufficient in combination to confirm whether a putative copper-resistant transformant is genuine. It is also preferable to study the cellular morphology of all putative transformants by light microscopy. A careful comparison of transformant with the parental strain (i.e. untransformed brewers' yeast) will indicate whether the transformant is in fact a genetically modified yeast or a contaminant.

30

- 18 -

Other methods for verifying plasmid transformants could be used if desired.

The yeast transformant thus obtained identified as NCYC 240 (pET13:1) was deposited at the National Collection of Yeast Cultures, Colney Lane, Norwich, NR4 7AU, United Kingdom, on December 12th 1984 under No. NCYC1545.

A single colony of NCYC 240 (pET13:1), which was verified as a true plasmid transformant by the methods described above, was grown on NEP glucose agar with 1mM CuSO₄ and inoculated into 200ml of NEP glucose supplemented with 0.2mM CuSO₄ (the liquid medium). The culture was incubated in a shake flask at 28°C for two days after which the full 200ml was inoculated into 5 litres of the same liquid medium. Cultures were grown in stirred

15 flasks at 20°C for four days. 5 litre cultures were then diluted, each into approximately 45 litres of lager wort. The worts were fermented for seven days and the yeast was harvested and repitched into an ale wort prepared as follows.

20 95% ale malt and 5% crystal malt were mashed with South Staffordshire water at 65.5°C for 90 minutes. Hops were added to 36 EBU and caramel was added to 30 EBU. The mixture was boiled for 90 minutes at 1 bar and subjected to a whirlpool stand of 30 minutes. The specific gravity 25 of the wort at collection was 1055° at 15°C.

The yeast was pressed and pitched at 1.5lb/barrel and the maximum fermentation temperature was 16°C. The beer was racked when the specific gravity had fallen to 1012°. The beer was conditioned at -1°C for 3 days. The 30 beer was filtered and diluted at 1038° gravity, 1008 PG, 24 EBU bitterness and 20 EBU colour. The ethanol content was 4%. The beer was found to be acceptable to drink.

A sample of the beer was dialysed and then concentrated by freeze-drying. The freeze-dried beer was 30 assayed for β -lactamase activity and it was found that there was no detectable β -lactamase activity.

- 19 -

Other methods for verifying plasmid transformants could be used if desired.

The yeast transformant thus obtained identified as NCYC 240 (pET13:1) was deposited at the National Collection of Yeast Cultures, Colney Lane, Norwich, NR4 7AU, United Kingdom, on December 12th 1984 under No. NCYC1545.

A single colony of NCYC 240 (pET13:1), which was verified as a true plasmid transformant by the methods described above, was grown on NEP glucose agar with 1mM CuSO₄ and inoculated into 200ml of NEP glucose supplemented with 0.2mM CuSO₄ (the liquid medium). The culture was incubated in a shake flask at 28°C for two days after which the full 200ml was inoculated into 5 litres of the same liquid medium. Cultures were grown in stirred

15 flasks at 20°C for four days. 5 litre cultures were then diluted, each into approximately 45 litres of lager wort. The worts were fermented for seven days and the yeast was harvested and repitched into an ale wort prepared as follows.

20 95% ale malt and 5% crystal malt were mashed with South Staffordshire water at 65.5°C for 90 minutes. Hops were added to 36 EBU and caramel was added to 30 EBU. The mixture was boiled for 90 minutes at 1 bar and subjected to a whirlpool stand of 30 minutes. The specific gravity 25 of the wort at collection was 1055° at 15°C.

The yeast was pressed and pitched at 1.5lb/barrel and the maximum fermentation temperature was 16°C. The beer was racked when the specific gravity had fallen to 1012°. The beer was conditioned at -1°C for 3 days. The 30 beer was filtered and diluted at 1038° gravity, 1008 PG, 24 EBU bitterness and 20 EBU colour. The ethanol content was 4%. The beer was found to be acceptable to drink.

A sample of the beer was dialysed and then concentrated by freeze-drying. The freeze-dried beer was 30 assayed for β -lactamase activity and it was found that there was no detectable β -lactamase activity.

assayed for β -lactamase activity and it was found that there was no detectable β -lactamase activity.

A similar procedure was followed with NCYC 240 lacking plasmid pET13:1 (i.e. unmodified NCYC 240), with the exception that the initial yeast culture in NEP glucose did not include copper sulphate. The beers produced by fermentation using both NCYC 240 and NCYC 240 (pET13:1) were judged to be essentially similar by routine Triangular Taste Test and Flavour Profile analyses (for a review of these methods see R.J. Anderson, 1983, Brewers' Guardian, November, p 25).

During the course of beer production with both forms of yeasts, samples of the yeast concerned were analysed in order to estimate cell number and cell viability. The results showed that there was little or no difference between the yeasts in these respects. In the case of the modified yeast, the proportion of cells containing the plasmid (pET13:1) was measured and it was found that relatively few cells lost the plasmid. Other factors were also monitored during fermentation with both the modified and the unmodified yeasts. These were: the drop in specific gravity of the wort with time, the increase in the number of cells with time and the size of the final crop of yeast. It was found that for each of those factors there was no significant difference between the use of the modified and the unmodified yeast.

Some of the modified yeast produced in the fermentation process was made available for use in a further, similar brewing process, while the excess yeast provided a source of β -lactamase.

The β -lactamase content was assessed by means of a biological assay and by means of an enzyme assay. In

- 20 -

such assays cells are harvested by centrifugation for 10 minutes and resuspended in 0.1M phosphate/citrate buffer pH 6.5 and disrupted using a Braun homogenizer. Glass beads and cell debris are removed by centrifugation (8000 \times g for 10 minutes) and the supernatant is recentrifuged (10000 \times g for 30 minutes). In assaying the resulting cell-free extracts by the biological assay, penicillin sensitive *E. coli* cells are plated on soft agar containing 25 μ g/ml ampicillin. 25 μ l of extract of NCYC 240 and NCYC 240 (pET13:1) are spotted on these plates which are subsequently incubated at 37°C. Spots of NCYC 240 (pET13:1) show strong growth of bacteria in the vicinity of the spot, spots of NCYC 240 do not. This indicates that NCYC 240 (pET13:1) cells obtained from a beer fermentation produce a substance capable of degrading penicillin and allowing the growth of sensitive *E. coli* cells, whereas cells of NCYC 240 (unmodified) do not possess this activity. The activity can be attributed to β -lactamase protein. Additional evidence that this activity can be attributed to a β -lactamase protein in NCYC 240 (pET13:1) can be obtained from the results of enzymic assays. In the first of these assays a qualitative paper disc detection system is employed, in which samples of yeast cell extracts are spotted on to Ceftriaxone discs impregnated with the chromogenic cephalosporin, Nitrocefin, which turns from yellow to red in the presence of a β -lactamase (BBL Microbiology Systems, Becton Dickinson and Company, Oxford) (C.H. O'Callaghan *et al.*, Antimicrobial Agents and Chemotherapy, 1972, 1, p 283). Cell-free extracts of NCYC 240 (pET13:1) from a beer fermentation turn the discs from yellow to red, whereas extracts of NCYC 240 (unmodified) show no colour change on the disc, thus demonstrating the presence of β -lactamase protein in NCYC 240 (pET13:1) but not in NCYC 240. The β -lactamase activity in yeast cell extracts is quantified by using the same chromogenic

- 20 -

cephalosporin, Nitrocefin, and the method described by C.H. O'Callaghan *et al.* (1972, Antimicrobial Agents and Chemotherapy, 1, p 283). Enzyme reactions are performed at 37°C in a 1cm cell containing a total volume of 1ml Nitrocefin solution (51.6 μ g of Nitrocefin 87/312 per ml in 0.05 M phosphate buffer, pH7) to which 20 μ l of cell-free yeast extract is added. The change in optical density of the reaction mixture is determined at 386 nm and 482 nm using a Beckman DU 7 spectrophotometer. In this way crude cell-free extracts of NCYC 240 (pET13:1) from a beer fermentation are capable of destroying 4.87 n moles of Nitrocefin 87/312 /min/mg protein at 37°C and pH 7.0 (protein estimates are obtained from the absorption of ultra violet light at 230 and 260 nm according to V.F. Kalb and R.W. Bernlohr (1977, Analytical Biochemistry, 82, p 362). Crude cell extracts of NCYC 240 (unmodified) and boiled extracts of NCYC 240 (pET13:1) (20 mins at 100°C) do not possess any β -lactamase activity.

Procedures similar to those described above in detail in relation to NCYC 240 have also been carried out with a proprietary strain of brewers' yeast, and the results obtained were very similar.

There now follows a description of the modification of NCYC 240 to enable it to produce a different protein material, namely β -D-glucanase. An endo-1,3-1,4- β -D-glucanase (EC 3.2.1.73) is an enzyme which catalyses the hydrolysis of alternating sequences of β -1,3 and β -1,4 - linked β -D-glucan, as in barley β -glucan and lichenan. The unique action of this enzyme precludes its ability to hydrolyse repeating sequences of β -1,3 - linked glucan, as in laminarin, and β -1,4 - linked glucan, as in carboxymethylcellulose (Barras, D.R., 1969, in "Cellulases and Their Applications",

25

20

30

- 22 -

156th meeting of the American Chemical Society, Sept. 11-12, 1968, Atlantic City, p 105).

The Gram-positive bacterium Bacillus subtilis produces an extra-cellular endo-1,3-1,4- β -D-glucanase which behaves in a similar fashion to that described above (Moscatelli, E.A. et al., 1961, Journal of Biological Chemistry, 236, p 2858; Ricketts, E.L. et al., 1962, Archives of Biochemistry and Biophysics, 69, p 371).

A chromosomal B. subtilis β -glucanase gene has been isolated by gene cloning from a strain of B. subtilis entitled NCIB 8565 (Hinchliffe, E., 1984, Journal of General Microbiology, 130, p 128). The active gene was found to reside upon a 3.5 kilo-base pair restriction endonuclease-Eco RI-fragment of DNA, which expressed a functional enzyme in E. coli. The cloned β -glucanase gene was shown to encode an enzyme specific for the hydrolysis of barley β -glucan, and was found to be predominantly extracytoplasmic in location in E. coli (Hinchliffe, 1984).

More recently the cloned β -glucanase gene has been located by deletion analysis on a 1.4 kb restriction endonuclease Pvu-Clal DNA fragment. A similar location has been assigned to a B. subtilis β -glucanase gene isolated from strain NCIB 2117 (Cantwell, B.A. & McConnell, D.J., 1983, Gene, 23, p 211). A more precise molecular characterization by DNA sequence analysis of the NCIB 2117 has recently been reported (Murphy, N. et al., 1984, Nucleic Acids Research, 12, p 5355).

Yeasts, including S. cerevisiae, produce several different types of β -glucanase; however, none is able to hydrolyse 1,3-1,4 - linked glucan (Abd-El-Ali, A.T.H. & Phaff, H.J., 1968, Biochemical Journal, 109, p 347). It

- 23 -

must therefore follow that yeast does not produce an endo-1,3-1,4- β -D-glucanase. The cloned β -glucanase gene of B. subtilis has therefore been introduced into S. cerevisiae, and it has been demonstrated that the gene is capable of encoding a biologically active protein in S. cerevisiae and that the enzyme activity is characteristic of that found in B. subtilis and E. coli (Hinchliffe, E. & Box, W.G., 1984, Current Genetics, 8, p 471). The expression of the cloned β -glucanase gene in S. cerevisiae is inefficient, relative to the amounts of biologically active enzyme produced in both B. subtilis and E. coli harbouring the cloned β -glucanase gene. However, the enzymic activity in yeast can only be detected in crude cell extracts of yeast harbouring the cloned gene (Hinchliffe, E. & Box, W.G., 1984). This may mean that the enzyme produced by yeast is incapable of being secreted from the cell and is intra-cellular in nature; unlike the enzyme produced by bacteria, which is extra-cellular.

To introduce the β -glucanase gene of B. subtilis into brewers' yeast NCYC 240, use was made of the shuttle vector pET113:1, that can replicate in both E. coli and S. cerevisiae, as mentioned above. The 3.5 kb Eco RI DNA fragment present in plasmid pEH83 was subcloned by in vitro re-arrangement into the single Bam HI site of pET113:1, as illustrated in more detail in the accompanying drawing. In the gene maps in the drawing the radially hatched arcs represent DNA from B. subtilis that carries the β -glucanase gene (AG), the broad, unfilled arcs represent chromosomal DNA indicating the location of LEU-2 and URA-3 genes. (Henderson, R.C.A., 1983, "The Genetics and Applications of Copper Resistance in Yeast", Ph.D thesis, University of Oxford), and the narrow arcuate black lines represent 2 μ m plasmid DNA and the thick arcuate black lines represent E. coli vector DNA.

- 24 -

sequences. Treatment with T4 DNA ligase following Eco RI digestion of pHB3 (Hinchliffe, E., 1984, Journal of General Microbiology, 130, p 1285) was performed under dilute DNA concentrations, thus favouring circularization of the two products of Eco RI digestion. One of those products is a circle of the DNA from the broad black arc of pHB3. On digestion of the products with the restriction endonuclease BglII that circle was broken at the BglII site to form a 3.5kb linear fragment. Meanwhile pET13:1 was digested and the resulting linear fragment was ligated with the linear fragment from pHB3, using T4 DNA ligase. That digestion and ligation were carried out at higher DNA concentrations, which favour recombination of the rearranged B. subtilis DNA in the Bam H1 site of pET13:1 (Henderson, R.C.A., 1983, "The Genetics and Applications of Copper Resistance in Yeast", Ph.D. thesis, University of Oxford). Ligation occurs because the endonucleases Bam H1 and BglII generate mutually compatible cohesive ends which join to form Bam H1/BglII hybrid sites which are not recognized by either Bam H1 or BglII. Transformants were selected in E. coli HB101 as being ampicillin-resistant, tetracycline-sensitive and β -glucanase positive in E. coli, thus enabling them to be distinguished from pHB3 in E. coli. The orientation of insertion of the re-arranged Eco RI fragment in pHB10 was determined by restriction endonuclease digestion followed by agarose gel electrophoresis. The new plasmid has been designated pHB10.

Plasmid DNA was isolated from HB101 harbouring the hybrid plasmid pHB10; this DNA was transformed into the brewers' yeast NCYC 240 as described previously. Resistance to copper was selected, as also described above. Plasmid transformants of NCYC 240 were verified by a combination of high-level resistance determinations

- 25 -

and β -lactamase assays, thus NCYC 240 (pHB10) was derived.

Single colonies of NCYC 240 (pHB10), NCYC 240 (pET13:1) and NCYC 240 were inoculated into 200ml of NEP (supplemented with 0.2mM CuSO₄ where appropriate). 5 glucose was incubated while being shaken at 27°C for 2 days, after which time they were inoculated each into the 2 litres of the same medium. After 3 days' growth at 27°C cells were harvested by centrifugation and washed twice in 0.1M phosphate/citrate buffer at pH 6.4 prior to cell disruption in a Braun homogenizer. Supernatants were prepared as described previously with the exception that each was dialysed overnight against 2 x 2l of 0.1M phosphate/citrate: pH 6.4. Crude cell extracts of the three NCYC 240 yeast were then subjected to β -glucanase assays as described by Hinchliffe & Box (1984). These assays demonstrated β -glucanase activity associated with cell-free extracts of NCYC 240 (pHB10) (1.17 n moles of reducing sugar liberated from barley β -glucan/min/mg protein at 40°C and pH 6.2), but no activity in cell-free extracts of either NCYC 240 (pET13:1) or NCYC 240. The yeast transformant thus obtained identified as NCYC 240 (pHB10) has been deposited at the National Collection of Yeast Cultures, Colney Lane, Norwich NR4 7AU, United Kingdom on December 12th 1984 under No. 1546.

A sample of the NCYC 240 (pHB10) yeast was grown in the manner described above and used in a brewing process similar to that described above in relation to NCYC 240 (pET13:1). The process yielded beer that was acceptable to drink and that contained substantially no endo-1,3-1,4- β -D-glucanase. Yeast from the brewing process was shown to contain the plasmid pHB10, specifying the production of β -glucanase. (1 n mole reducing sugar liberated from barley β -glucan/min/mg protein at 40°C and pH 6.4), so that part of it could be re-cycled (that is used in a subsequent brewing operation) and part of it could be used as a source of

- 26 -

the enzyme. Furthermore, crude cell extracts of NCYC 240 (pEHB10) derived from the brewing process contain β -lactamase enzyme activity (2.33 n moles of Nitrocefin 87/312 destroyed/min/mg protein at 37°C and pH 7.0) as well as β -glucanase enzyme activity. This demonstrates the feasibility of producing more than one heterologous protein at the same time in a genetically modified brewing yeast, such as NCYC 240.

Endo-1,3-1,4- β -D-glucanase obtained from B. subtilis is currently marketed as an enzyme preparation for use in the brewing industry in alleviating problems associated with the presence of unwanted β -glucan. The process described above may therefore be used to produce this enzyme for the same purpose.

CLAIMS

1. Process for the production of ethanol and a protein or peptide which is heterologous to yeast which comprises fermenting an aqueous sugar-containing medium with a yeast strain which has been genetically modified to be capable of expressing a heterologous protein or peptide, recovering the ethanol so formed, and obtaining the said heterologous protein or peptide from the fermentation products.
2. Process according to claim 1 in which the ethanol is recovered in the form of an aqueous potable liquid which is substantially free from yeast and from the said heterologous protein or peptide and which contains substantially all the water and ethanol of the said fermented medium.
3. Process according to claim 1 in which the ethanol is recovered from the said fermented medium in the form of an ethanolic distillate.
4. Process according to claim 2 in which the aqueous sugar-containing medium contains maltose as the wort.
5. Process according to claim 4 in which the aqueous sugar-containing medium is a barley malt-based beer wort.
6. Process according to claim 2, 4 or 5 in which 25 the fermentation is effected at 8 to 25°C.

7. Process according to claim 3 in which the aqueous sugar-containing medium is a fermentation medium for the production of potable distilled ethanol or power ethanol.


8. Process according to claim 7 in which the said medium is based on grain, potatoes, cassava, sugar cane, or sugar beet, optionally pretreated to convert cellulose and/or starch therein into fermentable sugars.

9. Process according to any one of claims 1 to 8 in which the fermentation is a substantially anaerobic fermentation.

10. Process according to any one of claims 1 to 9 in which the yeast used is a genetically engineered modification of an industrial strain of Saccharomyces cerevisiae, or S. carlsbergensis.

11. Process according to any one of claims 1 to 10 in which the said heterologous protein or peptide is obtained as protein or peptide retained in the yeast produced during the fermentation.

CONSTRUCTION OF THE β -GLUCANASE CUP-1 PLASMID pEHB10



Bacillus subtilis DNA (■■■■), pAT153/pBR325 DNA (■■), yeast chromosomal DNA (□), yeast 2 μ m plasmid DNA (—). The following gene locations are indicated by arrows: β -Glucanase (BG), β -lactamase (Ap) tetracycline resistance gene (Tc).

Restriction endonuclease cut sites are shown as follows: AvaI (A), BamH I (B), BglII (Bgl), ClaI (C), EcoRI (E), HindIII (H), KpnI (K), PvuI (P), PvuII (Pv), SacII (S) and XbaI (X).

**DECLARATION PURSUANT TO RULE 28, PARAGRAPH 4,
OF THE EUROPEAN PATENT CONVENTION**

The applicant has informed the European Patent Office that, until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, the availability of the micro-organism(s) identified below, referred to in paragraph 3 of Rule 28 of the European Patent Convention, shall be effected only by the issue of a sample to an expert.

IDENTIFICATION OF THE MICRO-ORGANISMS

Accession numbers of the deposits:

NCYC 1545
NCYC 1546

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.